Prostate Cancer
A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer.
March 5, 2025
Prostate Specific Antigen Density and Clinically-Significant Prostate Cancer: The Influence of Prostatic Volume.
March 5, 2025
Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC.
March 5, 2025
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy.
March 3, 2025
The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy.
March 3, 2025
How Standard of Truth Methodology Impacts Diagnostic PSMA-Targeting Radiopharmaceutical Evaluation: Learnings from the Phase 3 SPOTLIGHT Study.
February 28, 2025